Concerns with beta2-agonists in pediatric asthma - a clinical perspective

Beta2-adrenoreceptor agonists ( β2-agonists) are extensively used in the treatment of childhood asthma. However, there have been concerns regarding their adverse effects and safety. In 2005, the FDA commissioned a “Black Box Warning” communicating the potential for an increased risk for serious asthma exacerbations or asthma- related death with the regular use of LABAs. In a meta-analysis of controlled clinical trials, the incidence of severe adverse events appeared to be highest in the 4-11 year age group.

Source: Paediatric Respiratory Reviews - June 14, 2016 Category: Respiratory Medicine Authors: Elin T.G. Kersten, Gerard H. Koppelman, Bernard J. Thio Source Type: research